PLCB2 and breast neoplasm: Despite the complexity of the retinoid signaling in breast tumors, our results clearly demonstrate that PLC-β2 is a target for ATRA also in breast tumor cells and is part of the mechanism by means of which this agonist inhibits the acquisition of malignant properties by non-invasive breast tumor-derived cells as a consequence of low oxygen availability.